VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
September 01, 2022 16:30 ET
|
VBL Therapeutics
TEL AVIV, Israel and NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), a biotechnology company developing targeted medicines for immune-inflammatory diseases,...
VBL Therapeutics Announces Second Quarter 2022 Financial Results and Corporate Process to Explore Strategic Options
August 15, 2022 16:05 ET
|
VBL Therapeutics
TEL AVIV, Israel and NEW YORK, Aug. 15, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a biotechnology company developing targeted medicines for immune-inflammatory diseases, today...
VBL Therapeutics Announces Workforce Reduction
August 02, 2022 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel and NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases,...
VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer
July 19, 2022 16:01 ET
|
VBL Therapeutics
TEL AVIV, Israel and NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases,...
VBL Therapeutics to Participate in the Jefferies Healthcare Conference
May 31, 2022 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel and NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical stage biotechnology company developing first-in-class therapeutics for...
VBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 17, 2022 07:00 ET
|
VBL Therapeutics
OVAL Phase 3 top-line data expected in 2H 2022; with positive results, VBL anticipates submitting a BLA to the FDA in 1H 2023 Conference Call and Webcast at 8:30 a.m. ET Today TEL AVIV,...
VBL Therapeutics to Report First Quarter 2022 Financial Results on May 17
May 10, 2022 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel and NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for...
VBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in May
May 03, 2022 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel and NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for...
VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 28, 2022 16:05 ET
|
VBL Therapeutics
TEL AVIV, Israel and NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for...
VBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian Cancer
April 26, 2022 08:00 ET
|
VBL Therapeutics
FDA grants Fast Track designation to facilitate development and expedite the review of therapies with potential to treat serious unmet medical needs. The purpose of this designation is to bring...